FRI0190 INCIDENCE OF ANTIMALARIALS-INDUCED RETINOPATHY IN INFLAMMATORY RHEUMATIC DISEASES, USING OCT AND VISUAL FIELD TEST : A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: CAGNY Hélène DE, Jacques Morel, Bernard Combe, Cecile Gaujoux-Viala, Cédric Lukas
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Antimalarials (AM) are frequently used as first-line therapy in mild inflammatory diseases, because of a good benefit/risk ratio. Recently, their benefit on long term cardiovascular risk in RA patients has been demonstrated [1, 2]. Their most severe side effect is retinopathy, which can potentially lead to blindness, but remains reversible if detected early, provided the treatment is stopped. This complication has been described early [3], but its incidence remains uncertain. A recent update of the American Association of Ophtalmology (AAO) recommendations on screening for chloroquine and hydroxychloroquine retinopathy, suggests to screen patients under AM treatment, with a frequency depending on risk factors, and with the systematic and minimal use of Optical Coherence Tomography (OCT) and Visual Field (VF) test, completed by others tests if required [4]. <h3>Objectives:</h3> We aimed at estimating the exact incidence of AM-induced retinopathy, based on available published literature about this issue, with particular reference to detection performed with OCT and VF test. <h3>Methods:</h3> A systematic literature search was conducted in Pubmed, Cochrane and Embase databases until April 6th 2018, completed by a manual search in references from the resulting selected articles. We first selected all publications about the incidence of AM-associated retinopathy in patients treated for inflammatory diseases and included them in the systematic literature search. Among them, and in order to minimize heterogeneity of results, we focused on those which had used at least OCT and VF test, as recommended by the AAO, to perform a meta-analysis. Analysis was conducted using MetaXL for Microsoft Excel, applying the Inverse of Variance method. <h3>Results:</h3> Among the 3890 articles of potential interest, we selected 91 articles appropriately addressing the topic and included them in the systematic literature search. They were published between 1964 and 2018, with variable population sizes (10 to 3580 patients). Patients were treated with hydroxychloroquine, chloroquine or both for an inflammatory disease (usually lupus or rheumatoid arthritis). Mean treatment duration ranged from 1 to 14,1 years. Most of them were retrospectively designed, and diagnostic methods were diverse. For the aforementioned meta-analysis, we used data from 16 articles published between 2010 and 2018, in which every patient had at least OCT and VF Test. We found a pooled estimate of incidence of 6.05% (IC 95% [5.18 – 7.31]), with a I2 heterogeneity coefficient of 80%. <h3>Conclusion:</h3> We found a pooled incidence of approximately 6% of AM-induced retinopathy when OCT and VF test are used. However diagnostic criteria are not consensually well-defined, leading to heterogeneous data. <h3>References:</h3> [1] Rempenault C, Combe B, Barnetche T, et al. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis2017. [2] Mathieu S, Pereira B, Tournadre A, et al. Cardiovascular effects of hydroxychloroquine: a systematic review and meta-analysis. Ann Rheum Dis2017. [3] Hobbs H, Sorsby A, Freedman A: Retinopathy following chloroquine therapy. Lancet 1959; II: 478. [4] Marmor MF, Kellner U, Lai TY, et al, American Academy of Ophthalmology Statement. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision).Ophthalmology. 2016;123:1386-1394. <h3>Disclosure of Interests:</h3> Hélène DE CAGNY: None declared, Jacques Morel: None declared, Bernard Combe Consultant for: Abbvie, Bristol-Myers Squibb, Gilead, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Roche-Chugai, Sanofi, UCB, Cecile Gaujoux-Viala Consultant for: Speaking and/or consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, Merck-Serono, Medac, Nordic Pharma, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB Pharma., Speakers bureau: Speaking and/or consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, Merck-Serono, Medac, Nordic Pharma, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB Pharma., Cédric Lukas: None declared